Log in
NASDAQ:TYME

Tyme Technologies Stock Forecast, Price & News

$1.01
-0.02 (-1.94 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.01
Now: $1.01
$1.04
50-Day Range
$0.87
MA: $0.96
$1.03
52-Week Range
$0.85
Now: $1.01
$2.04
Volume180,800 shs
Average Volume664,119 shs
Market Capitalization$131.47 million
P/E RatioN/A
Dividend YieldN/A
Beta0.84
Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-18, a CMBT compound that is in preclinical stage for the treatment of solid tumors. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer, as well as with Mayo Clinic; and a strategic collaboration with Eagle Pharmaceuticals, Inc. to advance oral SM-88 for the treatment of patients with cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.
Read More
Tyme Technologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TYME
CUSIPN/A
Phone212-461-2315
Employees18

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.15 per share

Profitability

Net Income$-22,000,000.00

Miscellaneous

Market Cap$131.47 million
Next Earnings Date2/3/2021 (Estimated)
OptionableOptionable
$1.01
-0.02 (-1.94 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TYME News and Ratings via Email

Sign-up to receive the latest news and ratings for TYME and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions

How has Tyme Technologies' stock price been impacted by COVID-19 (Coronavirus)?

Tyme Technologies' stock was trading at $1.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TYME shares have decreased by 3.8% and is now trading at $1.01.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Tyme Technologies?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Tyme Technologies
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Tyme Technologies?

Wall Street analysts have given Tyme Technologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Tyme Technologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Tyme Technologies' next earnings date?

Tyme Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Tyme Technologies
.

How were Tyme Technologies' earnings last quarter?

Tyme Technologies, Inc. (NASDAQ:TYME) issued its quarterly earnings data on Thursday, November, 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.07) by $0.02.
View Tyme Technologies' earnings history
.

What price target have analysts set for TYME?

2 analysts have issued 12-month price objectives for Tyme Technologies' shares. Their forecasts range from $9.50 to $9.50. On average, they expect Tyme Technologies' stock price to reach $9.50 in the next year. This suggests a possible upside of 840.6% from the stock's current price.
View analysts' price targets for Tyme Technologies
.

Who are some of Tyme Technologies' key competitors?

What other stocks do shareholders of Tyme Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vaxart (VXRT), Allena Pharmaceuticals (ALNA), OpGen (OPGN), Selecta Biosciences (SELB), MEI Pharma (MEIP), Pfizer (PFE) and SCYNEXIS (SCYX).

Who are Tyme Technologies' key executives?

Tyme Technologies' management team includes the following people:
  • Mr. Steven E. Hoffman, Co-Founder, Chairman, CEO & Chief Science Officer (Age 57, Pay $900.79k)
  • Mr. Ben R. Taylor, Advisor (Age 43, Pay $710.98k)
  • Ms. Barbara C. Galaini, Acting Principal Financial Officer, Principal Accounting Officer & Corp. Controller (Age 62)
  • Brian Gill, Head of Corp. Communications & IR
  • Mr. James Biehl J.D., Chief Legal Officer & Sec. (Age 56)
  • Dr. Giuseppe Del Priore, Chief Medical Officer (Age 58)
  • Dr. Jonathan M. Eckard, Chief Bus. Officer (Age 46)
  • Mr. John Zucaro P.E., Sr. VP of CMC
  • Dr. John M. Rothman, Exec. VP of Product Devel. (Age 72)

What is Tyme Technologies' stock symbol?

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

Who are Tyme Technologies' major shareholders?

Tyme Technologies' stock is owned by a variety of retail and institutional investors. Top institutional investors include Morgan Stanley (0.12%) and JPMorgan Chase & Co. (0.03%). Company insiders that own Tyme Technologies stock include Barbara Galaini, David Carberry, Douglas A Michels, James Biehl, Michael Demurjian, Michele Ilene Korfin and Steve Hoffman.
View institutional ownership trends for Tyme Technologies
.

Which major investors are selling Tyme Technologies stock?

TYME stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. Company insiders that have sold Tyme Technologies company stock in the last year include Michael Demurjian, and Steve Hoffman.
View insider buying and selling activity for Tyme Technologies
.

Which major investors are buying Tyme Technologies stock?

TYME stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co.. Company insiders that have bought Tyme Technologies stock in the last two years include Barbara Galaini, David Carberry, Douglas A Michels, James Biehl, Michele Ilene Korfin, and Steve Hoffman.
View insider buying and selling activity for Tyme Technologies
.

How do I buy shares of Tyme Technologies?

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tyme Technologies' stock price today?

One share of TYME stock can currently be purchased for approximately $1.01.

How big of a company is Tyme Technologies?

Tyme Technologies has a market capitalization of $131.47 million. The company earns $-22,000,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. Tyme Technologies employs 18 workers across the globe.

What is Tyme Technologies' official website?

The official website for Tyme Technologies is www.tymeinc.com.

How can I contact Tyme Technologies?

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.